Susan Klaeger

The target landscape of clinical kinase drugs

Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm et al. · Science · 2017 · 845 citations · Full text

Tumor Biology, Proteomicsdb Database, Drug Target +14

A large peptidome dataset improves HLA class I epitope prediction across most of the human population

Siranush Sarkizova, Susan Klaeger, Phuong M. Le et al. · Nature Biotechnology · 2019 · 511 citations · Full text

Hla, Histocompatibility, Immunogenetics +14

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

Giacomo Oliveira, Kari Stromhaug, Susan Klaeger et al. · Nature · 2021 · 508 citations · Full text

Cancer Immunosurveillance, Melanoma, Immunology +5

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Gabriel K. Griffin, Jingyi Wu, Arvin Iracheta‐Vellve et al. · Nature · 2021 · 339 citations · Full text

Epigenetic Silencing, Cancer Immunosurveillance, Immunology +6

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Nimitha R. Mathew, Francis Baumgartner, Lukas M. Braun et al. · Nature Medicine · 2018 · 283 citations · Full text

Cell Therapy, Flt3-itd-mutant Leukemia Cells, Immunology +7